Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they know why. Photo by Adobe Stock/HealthDay News Current treatments ...

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

Aflibercept is a soluble decoy fusion protein that binds all isoforms of vascular endothelial growth factor (VEGF) with a greater binding affinity than ranibizumab. Intravitreal aflibercept is US Food ...

TUESDAY, Nov. 5, 2024 (HealthDay News) -- Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by ...

A Massachusetts General Hospital (MGH) investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by an overgrowth of blood vessels in the ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Of three ...

Sticking to the treatment schedule can be especially difficult. After you’re diagnosed, you usually need to have anti-VEGF injections about once a month, says Purnima Patel, MD, a clinical ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...